Research Funded

CART Cells for Sarcoma

Matthew Cascio, DO, University of Florida
Recipient of the: Dr. Richard and Valerie Aronsohn Memorial Research Award

Abstract: Metastatic osteosarcoma has a poor prognosis, yet systemic standard of care therapies renders patients with great morbidity and life-long disabilities. Thus, there is an urgency to discover less toxic and more effective th... Read More

Targeting the sarcoma tumor microenvironment using adrenergic receptor antagonists

Erin Dickerson, PhD, University of Minnesota – Twin Cities
Recipient of the: Dr. Richard and Valerie Aronsohn Memorial Research Award

Abstract: Vascular sarcomas (e.g. angiosarcomas, hemangiosarcomas, and hemangioendotheliomas) represent a therapeutic challenge since new treatment approaches have not occurred in several decades. We and others recently published re... Read More

Dissecting Mechanisms of Immune Mediated Radiation Resistance in Sarcomas

David Kirsch, MD, PhD, Duke University
Recipient of the: Race to Cure Sarcoma Research Award

Abstract: Soft tissue sarcomas represent a rare, aggressive, and complex group of malignancies. Patients with large or high-grade soft tissue sarcomas often receive radiation therapy in combination with surgery. Some sarcomas may oc... Read More

Towards precision immunotherapy for undifferentiated pleomorphic sarcoma (UPS)

Timothy Bowler, MBBCh, PhD, Memorial Sloan Kettering Cancer Center
Recipient of the: Sarcoma Foundation of America Research Award

Abstract: A tumor must evade destruction by the host’s immune system in order to grow. Immunotherapy works by enhancing or restoring the anti-tumor effects of the immune system. Checkpoint blockade has demonstrated efficacy in mul... Read More

Identifying chemoresistance pathways in Osteosarcoma

David Largaespada, PhD, University of Minnesota – Twin Cities
Recipient of the: Sarcoma Foundation of America Research Award

Abstract: Chemotherapy response is the primary determinant of long term survival for patients with osteosarcoma (OS), where patients who are resistant to chemotherapy are considered incurable. The ultimate goal of this study is to i... Read More

Rational biomarker-guided PARP inhibitor combination therapy in pediatric sarcomas

Anang Shelat, PhD, St. Jude Children’s Research Hospital
Recipient of the: Sarcoma Foundation of America Research Award

Abstract: The overall survival for recurrent and metastatic Ewing sarcoma (EWS) is dismal (15% and 10-30%, respectively). We previously showed that EWS has a defect in double-strand DNA (dsDNA) repair, and that the addition of Poly ... Read More

X
- Enter Your Location -
- or -